Background And Objectives: For patients with prostate cancer (PCa), PSMA PET better diagnose metastases than conventional imaging. In a systematic review and meta-analysis (INPLASY register, 2024311004), we aimed to summarize findings with pretreatment PSMA PET in patients with PCa that was localized according to conventional imaging and summarize how pretreatment PSMA PET had influence on biochemical recurrence (BCR)-free survival and overall survival (OS).
Methods: We searched for publications in Pubmed, Google Scholar, ClinicalTrials.gov, and reference lists between 2016 and February 2025. We summarized biochemical recurrence-free survival in Forest plots.
Results: Nine publications reported 1908 patients and showed that pretreatment PSMA PET was associated with survival. Three publications reported that pretreatment PSMA PET gave better 3-5-year BCR-free survival than conventional imaging (74% versus 57%). Two publications reported PSMA PET-risk for 389 patients. Those with PSMA PET-low-risk lived 5 years longer often than those with PSMA PET high-risk (84% versus 20%).
Conclusions: Pretreatment PSMA PET is widely used in the real world. Pretreatment PSMA PET supports personalized treatment and may explain why pretreatment PSMA PET improved BCR-free survival and OS. It is believed that pretreatment PSMA PET may facilitate future progress in care of patients with high-risk PCa.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3390/cancers17050841 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management Based on Pretreatment PSMA PET of Patients with Localized High-Risk Prostate Cancer Part 2: Prediction of Recurrence-A Systematic Review and Meta-Analysis.
Cancers (Basel)
February 2025
Center of Tobacco Control Research, 5230 Odense, Denmark.
Background And Objectives: For patients with prostate cancer (PCa), PSMA PET better diagnose metastases than conventional imaging. In a systematic review and meta-analysis (INPLASY register, 2024311004), we aimed to summarize findings with pretreatment PSMA PET in patients with PCa that was localized according to conventional imaging and summarize how pretreatment PSMA PET had influence on biochemical recurrence (BCR)-free survival and overall survival (OS).
Methods: We searched for publications in Pubmed, Google Scholar, ClinicalTrials.
A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer.
Eur J Nucl Med Mol Imaging
March 2025
Department of Medical Imaging, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Background: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is currently under evaluation for detecting clinically significant prostate cancer. The PSMA-PET/CT may complement the current standard diagnostic pathway for prostate cancer, which includes prostate-specific antigen (PSA) testing and multiparametric magnetic resonance imaging (mpMRI). This study evaluated the cost-effectiveness and quality of life impact of incorporating PSMA-PET/CT into this diagnostic algorithm.
View Article and Find Full Text PDFTreatment of metastatic castration-resistant prostate cancer: review of current evidence and synthesis of expert opinions on radioligand therapy.
Front Oncol
February 2025
Hong Kong Integrated Oncology Centre, Hong Kong, Hong Kong SAR, China.
Background: Despite the boom in the development of cancer management in the last decade, most patients with metastatic prostate cancer (PCa) eventually progress to metastatic castration-resistant PCa (mCRPC) and often require multiple lines of treatment. The treatment landscape of mCRPC has evolved rapidly in recent years, introducing various types of systemic therapies, including taxane-based chemotherapy, androgen receptor pathway inhibitors, bone-targeted radionuclides (e.g.
View Article and Find Full Text PDFSuperiority of Ga-PSMA-11 PET/CT over mpMRI for lateralization accuracy of diagnosing intra-glandular prostate cancer lesions: avoiding fluke targeting.
Ann Nucl Med
March 2025
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Objective: The aim of this study was to compare the diagnostic accuracy of Ga-PSMA-11 PET/CT and multiparametric MRI (mpMRI) in detecting unilateral and bilateral intra-glandular prostate cancer lesions.
Methods: A retrospective analysis was conducted on 73 prostate cancer patients diagnosed via biopsy, all of whom underwent both Ga-PSMA-11 PET/CT and mpMRI prior to surgery. Two independent readers, blinded to each other's results and to pathology findings, evaluated the imaging modalities to make a diagnosis of unilateral (left or right) or bilateral lesions for suspected prostate lesions.
Role of PSMA PET/CT in imaging and management of prostate cancer.
Curr Opin Oncol
February 2025
Department of Diagnostic Radiology and Nuclear Medicine.
Purpose Of Review: In the era of precision medicine, the introduction of FDA-approved prostate-specific membrane antigen (PSMA) targeting tracers has revolutionized prostate cancer imaging. These tracers enable functional positron emission tomography (PET) imaging, allowing for precise identification of the location and extent of prostate cancer spread. This review serves as a practical guide for multidisciplinary teams caring for prostate cancer patients, outlining the current approved uses of PET imaging with PSMA tracers and exploring its future applications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!